drugset
drugset / Trial / NCT00041574

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574 ↗

Phase 2 Terminated 7 enrolled Mallinckrodt
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this program is to evaluate the logistic issues and patient requirements for chronic pulsed INOmax delivery in ambulatory, home-care patients. To understand patient needs, patients with a variety of underlying diseases will be included. Safety of chronic therapy will be monitored by serial measurements of methemoglobin, platelet function assay and reported adverse events.

Timeline

Start
2002-04
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 0.5 ml Inhaled
Subject Nitric Oxide Other / unclassified 1 ml Inhaled
Subject Nitric Oxide Other / unclassified 2 ml Inhaled
Subject Nitric Oxide Other / unclassified 3 ml Inhaled
Subject Nitric Oxide Other / unclassified 4 ml Inhaled
Subject Nitric Oxide Other / unclassified 5 ml Inhaled
Subject Nitric Oxide Other / unclassified 6 ml Inhaled
Subject Nitric Oxide Other / unclassified 7 ml Inhaled
Subject Nitric Oxide Other / unclassified 8 ml Inhaled
Subject Nitric Oxide Other / unclassified 9 ml Inhaled
Subject Nitric Oxide Other / unclassified 10 ml Inhaled

Indications

lung disorder pulmonary hypertension sickle cell disease